Citadel Advisors’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-560
| Closed | -$4.14K | – | 13621 |
|
|
2025
Q2 | $4.14K | Buy |
560
+40
| +8% | +$351 | ﹤0.01% | 12245 |
|
|
2025
Q1 | $4.47K | Buy |
520
+132
| +34% | +$2.04K | ﹤0.01% | 13890 |
|
|
2024
Q4 | $13.9K | Sell |
388
-700
| -64% | -$36.2K | ﹤0.01% | 13426 |
|
|
2024
Q3 | $51.4K | Buy |
1,088
+300
| +38% | +$13.2K | ﹤0.01% | 11879 |
|
|
2024
Q2 | $39.6K | Buy |
788
+644
| +447% | +$46.6K | ﹤0.01% | 12004 |
|
|
2024
Q1 | $16.1K | Sell |
144
-344
| -70% | -$34.2K | ﹤0.01% | 13152 |
|
|
2023
Q4 | $28.3K | Sell |
488
-1,444
| -75% | -$58.1K | ﹤0.01% | 12310 |
|
|
2023
Q3 | $61.3K | Sell |
1,932
-2,320
| -55% | -$110K | ﹤0.01% | 11502 |
|
|
2023
Q2 | $350K | Buy |
4,252
+4,056
| +2,069% | +$593K | ﹤0.01% | 8701 |
|
|
2023
Q1 | $20.1K | Buy |
+196
| New | +$27.5K | ﹤0.01% | 13065 |
|
|
2022
Q3 | – | Sell |
-524
| Closed | -$61K | – | 13241 |
|
|
2022
Q2 | $61K | Sell |
524
-124
| -19% | -$11.7K | ﹤0.01% | 11806 |
|
|
2022
Q1 | $65K | Sell |
648
-1,176
| -64% | -$137K | ﹤0.01% | 12621 |
|
|
2021
Q4 | $284K | Sell |
1,824
-216
| -11% | -$42K | ﹤0.01% | 11045 |
|
|
2021
Q3 | $481K | Buy |
2,040
+1,156
| +131% | +$338K | ﹤0.01% | 9970 |
|
|
2021
Q2 | $300K | Sell |
884
-2,184
| -71% | -$827K | ﹤0.01% | 11276 |
|
|
2021
Q1 | $1.24M | Sell |
3,068
-3,108
| -50% | -$1.51M | ﹤0.01% | 7562 |
|
|
2020
Q4 | $4.11M | Buy |
6,176
+5,160
| +508% | +$2.87M | ﹤0.01% | 4005 |
|
|
2020
Q3 | $473K | Buy |
1,016
+264
| +35% | +$133K | ﹤0.01% | 7393 |
|
|
2020
Q2 | $440K | Buy |
+752
| New | +$257K | ﹤0.01% | 7306 |
|
Other funds holding MRSN
Citadel Advisors's MRSN Position: Q1 2026 in Review
Citadel Advisors sold out of Mersana Therapeutics (MRSN) in Q1 2026, closing a stake of 22,493 shares — an estimated $651K sold.
Citadel Advisors first reported a position in MRSN in Q2 2017 and held it in 27 quarters. The position peaked at $52M in Q4 2020. 1 fund tracked by Wall St. Rank holds MRSN as of Q1 2026.
- Citadel Advisors reported no remaining Mersana Therapeutics position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 22,493 Mersana Therapeutics shares in Q1 2026, an estimated $651K.
- Citadel Advisors first reported a position in Mersana Therapeutics in Q2 2017 and held it in 27 quarters.
- Citadel Advisors's Mersana Therapeutics position peaked at $52M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.